Expanding Coverage for Advanced Cancer Genomic Testing in Federal Programs.
This law mandates broader coverage for advanced cancer diagnostic tests, such as DNA sequencing, under Medicare, Medicaid, and CHIP. Crucially, the standard deductible for Medicare beneficiaries will be waived for these specific tests, reducing out-of-pocket costs. The goal is to enable doctors to tailor cancer treatments more effectively based on individual patient needs.
Key points
Medicare, Medicaid, and CHIP must cover advanced cancer diagnostic tests (e.g., genetic sequencing) used for treatment planning and monitoring.
The standard Medicare deductible will not apply to these specific tests, resulting in lower initial costs for beneficiaries.
Coverage is provided upon diagnosis, recurrence, and as needed to monitor disease progression or response to treatment.
Establishes an education program for physicians and the public on the importance of molecular diagnostics in cancer care.
Expired
Citizen Poll